Meblanios is an injectable combination of Aztreonam and Avibactam developed for hospital and institutional use where this combination therapy is clinically appropriate. Meblanios contains Aztreonam 1500 mg and Avibactam 500 mg per injection. The combination is relevant to the growing challenge of multidrug-resistant Gram-negative bacterial infections, particularly resistance mechanisms involving metallo-beta-lactamases (MBLs) and additional beta-lactamases....Read More

Meblanios is a term that can be explored within the broader field of antimicrobial resistance, particularly topics involving metallo-beta-lactamases and beta-lactamase-mediated resistance. One of the important compounds discussed in modern beta-lactamase research is Avibactam, a beta-lactamase inhibitor used in combination with selected antibacterial agents. Understanding the relationship between Meblanios, Avibactam, MBL resistance and beta-lactamase inhibition...Read More